fbpx Skip to main content
Home / Connect / Navega Therapeutics

Where Innovation Meets Investment

In the fight against the opioid epidemic, Navega Therapeutics is working with Biocom to help get their work out of the lab and into the world.

Founded in 2018, Navega Therapeutics is tackling the opioid epidemic with a novel gene therapy to treat chronic pain.

In 2019, Navega joined Johnson & Johnson’s life science incubator, JLABS, and partnered with Biocom to save through group purchasing, network with the community, and find opportunities for partnering and investment.

Navega executives attended a Biocom Gene Therapy event, where they connected with potential partners and got to share their vision and therapeutic approach with other attendees.

With support from Biocom, Navega has experienced continued savings and exposure during their preclinical stage, amplifying its mission to impact millions of patients worldwide.

Biocom connects innovation
to investment for California’s
life science industry.

Get connected.
Join Biocom’s community of life science companies that make an impact every day.

Get Connected

Our members’ success is what drives us.

Discover more members’ stories of connection.

Read More

Discover how Biocom connects innovation to investment for Navega and other California life science companies.

Read More

Find out how Biocom connects science and the supply chain for Argonaut and other California life science companies.

Read More

Find out how Biocom connects technology to biology for Cardea and other California life science companies.

Choose your news

Subscribe to Biocom newsletters tailored to yours interests.